Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume
EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer
Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC
G-CSF Allows for Efficacious Dose of Docetaxel With ARASENS Regimen in mHSPC